RxDoctor Payments DataLook up a doctor →

Aaron Haug, MD

Neurology · Englewood, CONPI 1962606467

Payments from drug & device makers

$121,680in general payments, 2019–2025

Across 984 payments — averaging $123.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$64K
  • AbbVie$37K
  • Teva Pharmaceuticals USA, Inc.$4K
  • UCB, Inc.$2K
  • Pfizer$1K
  • Medtronic$943
  • plus $12K from 54 others
$5,950in research payments, 2019–2025

Across 6 payments — averaging $991.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$5K
  • Medtronic$1K

What the payments were for

  • Consulting fees$1,0502%
  • Speaking & faculty fees$35,28062%
  • Travel & lodging$3231%
  • Food & beverage$20,51436%
  • Education$870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific21$64,110
AbbVie(2 entities)236$37,175
Teva Pharmaceuticals USA, Inc.37$4,457
UCB, Inc.67$2,023
Pfizer68$1,084
Medtronic(2 entities)25$943
Acadia Pharmaceuticals Inc18$822
EMD Serono, Inc.44$784
AstraZeneca(2 entities)16$721
Novartis38$677
SK Life Science, Inc.21$552
Amgen18$497
MDD US Operations, LLC22$484
Neurelis, Inc.18$474
TG Therapeutics, Inc.25$431
Tanabe Pharma America, Inc.20$420
Neurocrine Biosciences, Inc.20$415
Argenx US, Inc.16$356
Merz Pharmaceuticals, LLC15$352
Eisai Inc.17$335
Jazz Pharmaceuticals Inc.11$311
Sanofi12$246
Amneal Pharmaceuticals LLC13$232
Catalyst Pharmaceuticals, Inc.9$224
Acorda Therapeutics, Inc7$213
Lundbeck LLC11$206
Genentech USA, Inc.8$193
Lilly USA, LLC13$179
Axsome Therapeutics, Inc.7$179
Abbott6$154
Vanda Pharmaceuticals Inc.4$141
Biogen6$141
Ipsen Biopharmaceuticals, Inc8$140
Kyowa Kirin, Inc.6$128
Sunovion Pharmaceuticals Inc.11$126
Mallinckrodt Hospital Products Inc.5$125
Greenwich Biosciences, Inc.5$106
Livanova USA, Inc.5$100
Adamas Pharmaceuticals, Inc.5$99
Amylyx Pharmaceuticals, Inc.4$94
Scilex Pharmaceuticals Inc.5$83
CSL Behring3$76
Grifols USA, LLC3$75
Springworks Therapeutics, Inc.3$74
Supernus Pharmaceuticals, Inc.4$63
Banner Life Sciences, LLC2$57
Vertical Pharmaceuticals, LLC3$56
Johnson & Johnson(2 entities)2$55
Harmony Biosciences LLC2$55
Biohaven Pharmaceuticals, Inc.3$53
ANI Pharmaceuticals, Inc.2$51
Biohaven Pharmaceutical Holding Company Ltd.2$45
Cycle Pharmaceuticals Inc2$44
Avion Pharmaceuticals2$40
Xeris Pharmaceuticals, Inc.2$39
Travere Therapeutics, Inc.8$37
Bristol Myers Squibb2$36
Otsuka America Pharmaceutical, Inc.2$33
Alnylam Pharmaceuticals Inc.1$27
GE HealthCare1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121,680 in reported general payments places this provider in the 85th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$359,767
Medicare patients
314
Services billed
35,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate44$369,958
AustedoDeutetrabenazine18$243,835
NuplazidPimavanserin Tartrate48$224,622
RytaryCarbidopa/Levodopa74$100,822
Rasagiline Mesylate167$38,229
Carbidopa-LevodopaCarbidopa/Levodopa860$36,513
BotoxOnabotulinumtoxina19$28,836
NeuproRotigotine20$18,003
Carbidopa-Levodopa ErCarbidopa/Levodopa247$17,825
UbrelvyUbrogepant11$11,773
RivastigmineRivastigmine Tartrate144$11,091
Emgality PenGalcanezumab-Gnlm15$10,742
Aimovig AutoinjectorErenumab-Aooe12$8,654
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone16$5,041
AmantadineAmantadine Hcl65$4,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$415$369,95844 claims
Teva Pharmaceuticals USA, Inc.Austedo$4,457$243,83518 claims
Acadia Pharmaceuticals IncNuplazid$822$224,62248 claims
Amneal Pharmaceuticals LLCRytary$232$100,82274 claims
AbbVieBotox, Ubrelvy$37,175$40,61030 claims
UCB, Inc.Neupro$2,023$18,00320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 334 neurology providers in Colorado.

Other neurology in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →